BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

AMC Entertainment

Coinbase

FuelCell Energy

Canoo

Moderna

Pfizer

Plug Power

Romeo Power

Starbucks

Trillium Therapeutics

Tesla

So what did the stock market do today? Investors cheered on Pfizer stock and rallied behind infrastructure plays.

What Did the Stock Market Do Today, Aug. 23? 3 Big Stories to Catch Up On.

A major regulatory approval sparked a rally in coronavirus vaccine stocks.

Why Pfizer, BioNTech, and Moderna Stocks Jumped Today

The drugmaker's own stock is up 3% Monday morning, but that's nothing compared to the impact it's having on a couple of other healthcare companies.

Dual Wins for Pfizer Mean Big Jumps for These 2 Stocks

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for COMIRNATY® (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older. COMIRNATY is the first COVID-19 vaccine to be granted approval by the FDA. The vaccine has been available in the U.S. under Emergency Use Authorization (EUA) since December 11, 2020 (a

Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older

The vaccine will be marketed under the brand name Comirnaty, and the FDA hopes the approval will nudge unvaccinated people to get vaccinated.

Pfizer and BioNTech surge after the FDA officially approves its COVID-19 vaccine

The milestone could encourage more people to get vaccinated.

Pfizer's COVID-19 vaccine wins full approval from the FDA

The U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer-BioNTech's COVID-19 vaccine, making it the first vaccine to achieve that status. The mRNA-based vaccine has been available since late last year through an Emergency Use Authorization (EUA), and will continue to be offered under that designation for those aged 12 to 15 […]

FDA fully approves Pfizer-BioNTech's COVID-19 vaccine

The company's vaccine received emergency use authorization in December. Since then, more than 200 million doses of the vaccine have been administered in the U.S. alone.

Pfizer Vaccine Gets FDA Full Approval. Here Come the Mandates.

Pfizer Inc's (NYSE: PFE) COVID-19 vaccine that it developed in collaboration with German BioNTech is expected to receive full FDA approval on Monday – a few weeks ahead of the announced deadline of September 6th. The drug regulatory authority refrained from commenting any further on the news first reported by the New York Times.

Pfizer expecting full FDA approval for its COVID-19 vaccine today

What does the FDA approval of Pfizer-BioNTech's coronavirus vaccine mean for the stock market today. The post Pfizer-BioNTech Gains FDA Approval, 7 Things To Know Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Pfizer-BioNTech Gains FDA Approval, 7 Things To Know Right Now

The FDA has approved Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine, making it the first to receive full FDA approval. The vaccine will now be marketed as 'Comirnaty' to prevent COVID-19 infection in individuals 16 years and older.

Pfizer-BioNTech's COVID-19 Vaccine Becomes First To Receive Full FDA Approval

The shift from emergency use to full approval for the Pfizer-BioNTech shot could spur more people to get vaccinated and support more mandates.

The FDA just fully approved Pfizer's COVID-19 vaccine in a move that could lead to more vaccinations

U.S. officials hope full approval will boost trust in the jab.

FDA Approves Pfizer Coronavirus Vaccine, Report Says

The FDA's approval of the Pfizer and BioNTech Covid shot will likely spur more businesses to adopt vaccine mandates for workers.

FDA grants full approval to Pfizer-BioNTech's Covid shot, clearing path to more vaccine mandates

The shares of BioNTech SE (NASDAQ: BNTX) increased by over 6% pre-market. This is why it happened.

BioNTech Shares Increase Over 6% Pre-Market: Why It Happened

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) shares are trading higher following reports indicating the FDA is expected to fully approve Pfizer and BioNTech's COVID-19 vaccine this week. The two-dose shot was first cleared in December by the agency on an emergency use basis for people 16 years and older.

Why Pfizer And BioNTech Shares Are Trading Higher Today

The shot is currently being given in the US under an emergency use authorization.

FDA set to give Pfizer's COVID-19 vaccine full approval next week, report says

Pfizer Inc. PFE, -0.16% and U.S. shares of BioNTech SE BNTX, +5.08% rose in the extended session Friday following a report that the drug makers will likely get full Food and Drug Administration approval for their COVID-19 vaccine sometime next week. Pfizer shares rose more than 2% after hours, following a 0.2% decline to close at $48.72, and BioNTech's ADRs rallied more than 5%, following a 5.1% gain to close at $348.68.

Pfizer, BioNTech stocks rise on report FDA could fully approve COVID-19 vaccine

Pfizer Inc. PFE, +2.71% and U.S. shares of BioNTech SE BNTX, +8.28% rose in the extended session Friday following reports that the drug makers will likely get full Food and Drug Administration approval for their COVID-19 vaccine sometime next week.

Pfizer and BioNTech shares rise on report FDA could fully approve COVID-19 vaccine next week

Approval for Pfizer's vaccine — which the New York Times and Politico say is on track for next week — could boost vaccination rates as the pandemic resurges, some experts believe.

Pfizer's Covid Vaccine Reportedly Set For Full FDA Approval Next Week

Novavax

The U.S. is ramping up its ability to produce more COVID-19 vaccines.

Why Moderna, BioNTech, and Novavax Stocks Climbed Today

The Food and Drug Administration could approve the Pfizer and BioNTech Covid-19 vaccine on Monday, The New York Times reported.

Full approval for Pfizer Covid vaccine could come from FDA Monday, report says

The new licensing timeline is speedier than originally expected, the outlet reported.

The FDA hopes to fully approve the Pfizer vaccine on Monday, The New York Times reported

BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 5.5% at $350 Friday morning after Canaccord Genuity maintained a Buy rating on the stock and raised its price target from $240 to $450. The German biotechnology company has received a number of analyst rating updates over the past week.

News for BioNTech SE Stock (BNTX)